



# Evolut Clinical Guideline 3240 for Tibsovo™ (ivosidenib)

<b>Guideline Number:</b> Evolut_CG_3240	<b><u>Applicable Codes</u></b>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc. © 2018 - 2025 Evolut. All rights Reserved.</i>		
<b>Original Date:</b> August 2018	<b>Last Revised Date:</b> December 2025	<b>Implementation Date:</b> December 2025

## TABLE OF CONTENTS

<b>STATEMENT</b> .....	<b>2</b>
PURPOSE .....	2
<b>INDICATIONS</b> .....	<b>2</b>
ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS) .....	2
CHOLANGIOCARCINOMA .....	2
<b>CONTRAINDICATIONS/WARNINGS</b> .....	<b>3</b>
<b>EXCLUSION CRITERIA</b> .....	<b>3</b>
<b>CODING AND STANDARDS</b> .....	<b>4</b>
CODES .....	4
APPLICABLE LINES OF BUSINESS .....	4
<b>POLICY HISTORY</b> .....	<b>4</b>
<b>LEGAL AND COMPLIANCE</b> .....	<b>4</b>
GUIDELINE APPROVAL .....	4
<i>Committee</i> .....	4
DISCLAIMER .....	4
<b>REFERENCES</b> .....	<b>5</b>

## STATEMENT

### Purpose

To define and describe the accepted indications for Tibsovo (ivosidenib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

## INDICATIONS

### Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

### Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

- The member has AML with a documented IDH1 gene-mutation as detected by an FDA approved test, e.g. Abbott RealTime IDH1 Assay, and Tibsovo (ivosidenib) may be used in ANY of the following clinical settings:
  - As monotherapy OR in combination with Vidaza (azacitidine) for newly diagnosed AML OR
  - As monotherapy for relapsed/refractory AML
- MDS: Tibsovo (ivosidenib) may be used for members with relapsed/refractory MDS with a documented IDH1 mutation.

### Cholangiocarcinoma

- Tibsovo (ivosidenib) may be used as monotherapy for IDH1-mutation positive recurrent unresectable or metastatic cholangiocarcinoma, that has progressed on at least one prior line of therapy. Confirmation of IDH-1 mutation positivity (by any appropriate test) is required.

## CONTRAINDICATIONS/WARNINGS

- US Boxed Warning
  - Patients treated with ivosidenib have experienced symptoms of differentiation syndrome, which can be fatal. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

## EXCLUSION CRITERIA

- Disease progression on or following Tibsovo (ivosidenib) or Tibsovo (ivosidenib) containing regimen.
- Lack of documentation of IDH-1 mutation positivity.
- Dosing exceeds single dose limit of Tibsovo (ivosidenib) 500 mg.
- Treatment exceeds the maximum limit of 60 (250 mg) tablets/month.
- Investigational use of Tibsovo (ivosidenib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
  - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

## CODING AND STANDARDS

### Codes

- J8999 - ivosidenib

### Applicable Lines of Business

<input type="checkbox"/>	CHIP (Children's Health Insurance Program)
<input checked="" type="checkbox"/>	Commercial
<input checked="" type="checkbox"/>	Exchange/Marketplace
<input checked="" type="checkbox"/>	Medicaid
<input type="checkbox"/>	Medicare Advantage

## POLICY HISTORY

Date	Summary
December 2025	<ul style="list-style-type: none"> <li>• Converted to new Evolent guideline template</li> <li>• This guideline replaces UM ONC_1340 Tibsovo (ivosidenib)</li> <li>• Updated references</li> </ul>
December 2024	<ul style="list-style-type: none"> <li>• Added Evolent disclaimer language</li> <li>• Added Coding Information section with HCPCS code</li> <li>• Updated NCH verbiage to Evolent</li> <li>• Updated references</li> </ul>

## LEGAL AND COMPLIANCE

### Guideline Approval

#### Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

#### Disclaimer

*Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent*

uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

## REFERENCES

1. Zhu AX, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. *JAMA Oncol.* 2021 Nov 1;7(11):1669-1677. doi: 10.1001/jamaoncol.2021.3836.
2. Woods A, et al. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. *Clin Cancer Res.* 2024 Apr 1;30(7):1226-1231. doi: 10.1158/1078-0432.CCR-23-2234.
3. Montesinos P, et al. Ivosidenib and Azacitidine in *IDH1*-Mutated Acute Myeloid Leukemia. *N Engl J Med.* 2022 Apr 21;386(16):1519-1531. doi: 10.1056/NEJMoa2117344.
4. DiNardo CD, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. *N Engl J Med.* 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984.
5. Tibsovo prescribing information. Servier Pharmaceuticals LLC. Boston, MA 2023.
6. Clinical Pharmacology Elsevier Gold Standard 2025.
7. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
8. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
9. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
10. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol.* 2014 Apr 20;32(12):1277-80.
11. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
12. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.